Response to Carboplatin and Paclitaxel in the treatment of hereditary breast ovarian cancer syndrome (HBOC): a case report

被引：0

作者：

Mehmood, Faisal ^{[1
]}

Touseef, Mumtaz ^{[2
]}

Ashraf, Amna ^{[2
]}

Rai, Izza Ali ^{[3
]}

机构：

[1] Combined Mil Hosp, Dept Radiol, Lahore, Pakistan

[2] Combined Mil Hosp, Dept Med, Lahore, Pakistan

[3] Combined Mil Hosp, Dept Vasc Surg, Lahore, Pakistan

来源：

JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION | 2024年 / 74卷 / 12期

关键词：

Hereditary breast ovarian cancer; Breast cancer; Ovarian cancer; HBOC; BRCA; PALB2; Chemotherapy; Carboplatin; Paclitaxel; PREVALENCE; MUTATIONS;

D O I：

10.47391/JPMA.20059

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The co-occurrence of primary breast cancer and primary ovarian cancer is an exceptional hereditary phenomenon and results from inherent mutations in critical genes like a unique case of hereditary breast-ovarian cancer syndrome (HBOC) reported in Combined Military Hospital, Lahore, Pakistan. It was marked by pathogenic variants in RAD51D, PALB2, CHEK1, and TP53 genes. Remarkably, the patient exhibited an outstanding response to the chemotherapy agents, Carboplatin and Paclitaxel. This dynamic treatment not only led to nearly complete remission of high-grade ovarian serous cancer but also triggered regression in grade-2 invasive ductal breast cancer after just a few rounds of chemotherapy. Consequently, what started as palliative care evolved into a curative triumph.

引用

页码：2184 / 2187

页数：4

共 50 条

[1] Paclitaxel with carboplatin for the treatment of ovarian cancer
Neijt, JP
Lund, B
SEMINARS IN ONCOLOGY, 1996, 23 (06) : 2 - 4
[2] Hereditary-Breast Ovarian Cancer (HBOC) syndrome: History, tumor complement and management
Lynch, Henry T.
Casey, M. J.
Snyder, C.
Lynch, J. F.
TUMOR BIOLOGY, 2006, 27 : 7 - 7
[3] A case series of sporadic breast and ovarian cancers in Salentinian families with BRCA mutation-associated Hereditary Breast and Ovarian Cancer (HBOC) syndrome
De Matteis, E.
De Giorgio, M. R.
Tarantino, P.
Ronzino, G.
Ciccarese, M.
Paolelli, L.
Forcignano, R.
Chiuri, V. E.
Cairo, G.
Palma, L.
Mauro, S.
Surico, G.
ANNALS OF ONCOLOGY, 2016, 27
[4] Breast cancer detection, treatment and outcome in women with hereditary breast and ovarian cancer (HBOC) - Alberta experience.
Hughes, R
Zochodne, B
Lilley, M
Blaikie, K
Kieffer, S
Wagter, L
Gilchrist, D
Barker, K
Fick, G
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 228 - 228
[5] Hereditary breast and ovarian cancer syndrome (HBOC) diagnosis impacts more the life quality of women than men: A case-control report
Barbosa Oliveira, Francisca Fernanda
de Barros Silva, Paulo Goberlanio
Silva-Fernandes, Isabelle JoyceLima
Picanco-Albuquerque, Clarissa Gondim
dos Santos Luciano, Maria Claudia
Barbosa Bezerra, Maria Julia
Sant Anna, Rosane Oliveira
Bitencourt, Flavio Silveira
Alves Lima, Marcos Venicio
CANCER RESEARCH, 2021, 81 (04)
[6] FACTORS ASSOCIATED WITH GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME (HBOC): AN INTEGRATIVE REVIEW
Robinson, Kathryn
Underhill, Meghan
ONCOLOGY NURSING FORUM, 2018, 45 (02)
[7] Paclitaxel plus carboplatin in the treatment of ovarian cancer
Ozols, RF
SEMINARS IN ONCOLOGY, 1999, 26 (01) : 84 - 89
[8] A case of simultaneous breast cancer and ovarian cancer based on a hereditary breast and ovarian cancer syndrome
Kotaka, Saki
Yasui, Hiroaki
Tsubouchi, Hirofumi
Mori, Masahiko
Kotani, Haruru
Yoshimura, Akiyo
Ouchi, Akira
Okuno, Masataka
Komori, Koji
Shimizu, Yasuhiro
Suzuki, Shiro
NAGOYA JOURNAL OF MEDICAL SCIENCE, 2023, 85 (04): : 814 - 821
[9] Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis
Reiko Yoshida
Breast Cancer, 2021, 28 : 1167 - 1180
[10] Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe
Marmolejo, David Humberto
Wong, Mark Yu Zheng
Bajalica-Lagercrantz, Svetlana
Tischkowitz, Marc
Balmana, Judith
EUROPEAN JOURNAL OF MEDICAL GENETICS, 2021, 64 (12)

← 1 2 3 4 5 →